`
`
`
`CURRICULUM VITAE
`
`
`
`
`
`Personal Data:
`
`Telephone:
`cell
`
`e-mail
`
`
`Education:
`
`1987-1988 Post-Doctoral Research Fellow; Joint appointment in the Departments of Pediatric
`Cardiology (The University of Michigan Medical School) & Pharmaceutics (The
`University of Michigan College of Pharmacy)
`
`
`
`
`
`
`
`
`
`
`
`
`
` 816-235-1624
` 913-424-0853
` johnstont@umkc.edu
`
`
`
`
`1987 Ph.D.; Department of Pharmaceutics, College of Pharmacy, University of Minnesota,
` Minneapolis, Minnesota 55455
`
`1980 B.S.; College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455
`
`
`Professional Experience:
`
`2008 – Present Professor of Pharmaceutics, Division of Pharmaceutical Sciences, School of
`Pharmacy, University of Missouri-Kansas City
`
`1995 – 2008 Associate Professor of Pharmaceutics, Division of Pharmaceutical Sciences,
`School of Pharmacy, University of Missouri-Kansas City
`
`1988 – 1994 Assistant Professor of Pharmaceutics / Pharmacokinetics, Department of
`Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of Illinois, Chicago, IL
`
`
`Licensure:
`
`Licensed to practice pharmacy in the state of Minnesota-License number = 113584-8
`Licensed to practice pharmacy in the state of Kansas-License number = 13242
`
`
`
`
`
`
`
`
`
`
`
` 1
`
`Page 1
`
`RB Ex. 2004
`BDSI v. RB PHARMACEUTICALS LTD
`IPR2014-00325
`
`

`

`
`
`Nov 2007
`
`July 2002
`
`July 1994
`
`May 1994
`
`May 1990
`
`May 1988
`
`
`Awards and Citations:
`
`March 2008 Rho Cho Pharmacy Honor Society Faculty Member of the Year, School of Pharmacy,
`University of Missouri-Kansas City, Kansas City, MO
`Outstanding Teacher of the Year, School of Pharmacy, University of Missouri-
`Kansas City, Kansas City, MO
`Designated as a “Master Instructor” in the field of pharmaceutics by the American
`Association of Colleges of Pharmacy, Kansas City, MO
`Cited as an Outstanding Pharmaceutical Educator in the U.S. at the meeting of the
`American Association of Colleges of Pharmacy, Albuquerque, NM.
`Outstanding Teacher of the Year, College of Pharmacy, University of Illinois,
`Chicago, IL 60612
`Outstanding Teacher of the Year, College of Pharmacy, University of Illinois,
`Chicago, IL 60612
`Received the American Society for Artificial Internal Organs Travel Fellowship Award
`for the Society's 34th Annual Meeting in Reno, Nevada
`August 1987 Article by Ms. Kristin Jenkins entitled "Implantable Delivery Systems Revolutionizing
`How We Take Drugs", The Medical Post (The Maclean Hunter Newspaper for the
`Canadian Medical Profession), Volume 23, No. 29.
`August 1987 Article by Ms. Pamela Harrison entitled "Bioprosthetic Heart Valves Being Saved by
`Novel Drug Delivery System", Ontario Medicine (a newspaper for Ontario's Medical
`Profession), Volume 6, No. 16
`Theodore J. Rowell Fellowship, University of Minnesota, Minneapolis, Minnesota
`55455
`Rho Chi Honor Society Award, University of Minnesota, Minneapolis, Minnesota
`55455
`Rho Chi Research Award, University of Minnesota, Minneapolis, Minnesota 55455
`
`1983-1984
`
`1981
`
`
`
`
`
`1980
`
`
`Current and/or Past Professional and Honorary Memberships:
`
`American Association of Pharmaceutical Scientists (AAPS)
`American Pharmaceutical Association (APhA)
`American Association of Colleges of Pharmacy (AACP)
`Minnesota State Pharmaceutical Association (MSPhA)
`Kansas Pharmacists Association (KPhA)
`Rho Chi Pharmacy Honor Society
`Controlled Release Society (CRS)
`Parenteral Drug Association (PDA)
`Who's Who in the Midwest
`Who's Who in the United States
`Who's Who in Science and Engineering
`Who's Who in Medicine and Healthcare
`Who’s Who in American Education
`Listed in "The International Directory of Distinguished Leadership"
`New York Academy of Sciences
`Secretary for the Teachers of Pharmaceutics Section of AACP (2002-2004)
`
`
`
` 2
`
`Page 2
`
`

`

`
`Editorial Experience:
`
`1987 - present
`
`
`
`
`
`
`
`Reviewer
`
`
`
`
`
`
`
`2002 – present
`2007 – present
`
`
`Grant Review Experience:
`
`1987 - 1994
`1995 - 1999
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Journal of Pharmaceutical Science & Technology
`Journal of Pharmaceutical Science
`Pharmaceutical Research
`International Journal of Pharmaceutics
`Journal of Biological Chemistry
`Drug Development and Industrial Pharmacy
`Atherosclerosis
`Pharmaceutical Development and Technology
`Journal of Pharmacy and Pharmacology
`Molecular Pharmaceutics
`European Journal of Pharmaceutics and Biopharmaceutics
`
`Editorial Board Member
`
`Journal of Pharmacy and Pharmacology
`Journal of Ocular Biology, Diseases, and Informatics
`
`Served as a Reviewer for the American Heart Association of Illinois
`Served as a Reviewer for the American Heart Association-Heartland
`Consortium; formerly the AHA-Kansas Affiliate
`Serve as an ad hoc reviewer for the National Institutes of Health (NIH)
`
`2000-present
`
`
`
`Teaching, Research, and Administrative Activities:
`
`1988-1994
`
`Served on the College of Pharmacy's Educational Policy Committee (University of
`Illinois). Was elected by colleagues for three consecutive two-year terms.
`Taught a graduate-level course on "Stabilization of Pharmaceutical Systems" with
`Emphasis on Recombinant Proteins.
`Participated in team-taught pharmaceutics classes in the College of Pharmacy's
`professional Pharm.D. curriculum.
`August 1990 Lectures presented to the U.S. Food and Drug Administration on Pharmacokinetics
`and Stabilization of Pharmaceutical Systems.
`Lectures presented to U.S. Food and Drug Administration on Dissolution and In
`Vitro/In Vivo Correlation.
`
`1989-2004
`
`1988-2004
`
`June 2000
`
`
`
`
`
`
`
`
`
` 3
`
`Page 3
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`Intentionally left blank
`
`Intentionally left blank
`
`Intentionally left blank
`
`Intentionally left blank
`
`
`Publications
`
`
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`T.P. Johnston, T.A. Korolenko, Restoration of serum lipids and cardiac proteases following an acute
`challenge of the hyperlipidemic agent, poloxamer 407, in mice. In Preparation, 2014.
`
`T.P. Johnston, P. Koulen. Effects of sustained dyslipidemia on the neurodegeneration of retinal
`ganglion cells in diabetic retinopathy. In Preparation, 2015.
`
`T.A. Korolenko, T.P. Johnston. Chap. X: Aspartate protease cathepsin D in liver and heart injury,
`pathophysiology and therapy, In: Cathepsin D: Molecular Characterization, Pathophysiological
`Functions, and Health Implications, J.B. Cohen, L.P. Ryseck (Eds), Nova Science Publishers, Inc.,
`Hauppauge, NY, 2015, Accepted.
`
`Johnston, T.P., Chap. 1: Anatomy and physiology of the oral mucosa and its relevance to local and
`systemic oral mucosal drug delivery, In: Oral Mucosal Drug Delivery and Therapy, M. Rathbone, S.
`Senel, I. Pather (Eds), Advances in Delivery Science and Technology Series, Springer, New York, NY,
`2014, In Press.
`
`T.P. Johnston, T.A. Korolenko. Chap. 1: Statin treatment in experimental lipemia and
`atherosclerosis: The similarities and differences with humans, In: Statins: Medical Uses, Mechanisms
`of Action, and Clinical Outcomes, ER Travers (Ed), Nova Science Publishers, Inc., Hauppauge, NY,
`2014. ISBN: 978-1-63463-096-2
`
`V.M. Loginova, T.A. Korolenko, T.P. Johnston, F.V. Tuzikov, N.V. Goncharova. Lipoprotein fractions
`and subfractions and heart proteases during acute lipemia in a murine model of atherosclerosis.
`Medimond International Proceedings, Vol #:pp.-pp., 2014, In Press.
`
`T.A. Korolenko, T.P. Johnston, E. Pisareva, E. Filjushina, E. Machova. Serum cystatin C and
`chitotriosidase in acute dyslipidemia: Can they serve as potential early biomarkers for
`atherosclerosis? J. Pharmacol. Toxicol. Submitted, 2014.
`
`A.D. Vadlapudi, R.K. Vadlapatla, T.P. Johnston, A.K. Mitra, Peptides and Proteins: Buccal
`Absorption, In: J. Swarbrick (Eds.), Encyclopedia of Pharmaceutical Science and Technology, 4th
`Edition, Taylor & Francis, NY (2013) pp. 2525-2541.
`
`T.A. Korolenko, T.P. Johnston, N.I. Dubrovina, Y.A. Kisarova, S.Y. Zhanaeva, N.A. Zhukova, Effect
`of poloxamer 407 administration on the serum lipids profile, anxiety level, and protease activity in the
`heart and liver of mice, Interdiscip. Toxicol. 6(1),18-25, 2013.
`
`T.A. Korolenko, F.V. Tuzikov T.P. Johnston, N.A. Tuzikova, Y.A. Kisarova. The influence of repeated
`administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart.
`Can. J. Physiol. Pharmacol. 90, 1456-1468, 2012.
`
`
`6.
`
`
`7.
`
`
`
`8.
`
`
`9.
`
`
`10.
`
`
`11.
`
`
`12.
`
`
`13.
`
`
`14.
`
`
`15.
`
`T.P. Johnston, T. Yasuda, M. Shinohara, M. Inoue, T. Ishida. The effect of poloxamer 407 on the
`functional properties of HDL in mice, J. Pharm. Pharmacol., 64, 677-687, 2012.
` 4
`
`Page 4
`
`

`

`
`16.
`
`
`17.
`
`
`18.
`
`
`19.
`
`
`20.
`
`
`21.
`
`
`22.
`
`
`23.
`
`
`24.
`
`
`25.
`
`
`26.
`
`
`27.
`
`
`28.
`
`
`29.
`
`
`30.
`
`
`T.A. Korolenko, F.V. Tuzikov, M.S. Cherkanova, T.P. Johnston, N.A. Tuzikova. Influence of
`atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice
`with poloxamer 407-induced lipemia. Can. J. Physiol. Pharmacol, 90, 141-153, 2012.
`
`T.P. Johnston, P. Mondal, D.J. Pal, S. MacGee, A.J. Stromberg, H. Alur. Canine periodontal disease
`control using a clindamycin hydrochloride gel. J. Vet. Dent., 28, 224-229, 2011.
`
`T.A. Korolenko, M.S. Cherkanova, T.P. Johnston, E.A. Gashenko, B.I. Yu. Chapter 8: Cystatin C,
`Atherosclerosis, and Lipid-lowering Therapy With Statins, In: Cystatins: Protease Inhibitors,
`Biomarkers, and Immunomodulators, J.B. Cohen, L.P. Ryseck (Eds), Nova Science Publishers, Inc.,
`Hauppauge, NY, 187-204, 2011. ISBN 978-1-61209-343-7
`
`H. Alur, P. Mondal, T.P. Johnston. Evaluation of TRI-726 as a drug delivery platform. Drug Develop.
`Indust. Pharm., 37, 995-1001, 2011.
`
`T.A. Korolenko, M.S. Cherkanova, F.V. Tuzikov, T.P. Johnston, N.A. Tuzikova. Influence of
`atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity of
`mice with Triton WR-1339-induced lipemia, J. Pharm. Pharmacol., 63, 833-839, 2011.
`
`M.A. Ruby, B. Goldenson, G. Orasanu, T.P. Johnston, J. Plutzky, R.M. Krauss. VLDL hydrolysis by
`LpL activates PPARa through generation of unbound fatty acids, J. Lipid Res., 51, 2275-2281, 2010.
`
`T.A. Korolenko, F.V. Tuzikov, T.P. Johnston, N.A. Tuzikova, E.E. Filjushina, V.M. Loginova, N.G.
`Savchenko. Influence of poloxamer 407 on fractional and subfractional composition of serum
`lipoproteins in mice, HEALTH, 2, 722-730, 2010.
`
`T.P. Johnston, Poloxamer 407 as a general lipase inhibitor: its implication in lipid metabolism and
`atheroma formation in C57BL/6 mice, J. Pharm. Pharmacol., 62, 1807-1812, 2010.
`
`P. Karla, R. Earla, S. Boddu, T.P. Johnston, D. Pal, A.K. Mitra. Molecular expression and functional
`evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr. Eye Res., 34, 1-9,
`2009.
`
`X. Zhou, T.P. Johnston, D. Johansson, P. Parini, K. Funa, J. Svensson, G.K. Hansson.
`Hypercholesterolemia leads to elevated TGF-b1 activity and T helper 3-dependent autoimmune
`responses in atherosclerotic mice. Atherosclerosis, 204, 381-387, 2009.
`
`T.P. Johnston, Poloxamer 407 administration to C57BL/6 mice causes an elevation in the soluble
`adhesion molecules, intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1
`(sVCAM-1), and sE-selectin, J. Pharm. Pharmacol., 61, 1681-1688, 2009.
`
`H. Tanaka, T. Ishida, T.P. Johnston, T. Yasuda, T. Ueyama, Y. Kojima, R.K. Kundu, T.
`Quertermous, Y. Ishikawa, K. Hirata, Role of endothelial lipase in plasma HDL levels in a murine
`model of hypertriglyceridemia, J. Atheroscler. Thromb., 16, 327-338, 2009.
`
`T.P. Johnston, D.J. Waxman, The induction of atherogenic dyslipidemia in poloxamer 407-treated
`mice is not mediated through PPARa, J. Pharm. Pharmacol., 60, 753-759, 2008.
`
`N. Wongsiriroj, R. Piantedosi, K. Palczewski, I.J. Goldberg, T.P. Johnston, E. Li, W.S. Blaner. The
`molecular basis of retinoid absorption: A genetic dissection. J. Biol. Chem., 283, 13510-13519, 2008.
`
`T.P. Johnston, D.J. Waxman, Circulating free fatty acids are increased independently of PPARg
`activity after administration of poloxamer 407 to mice, Can. J. Physiol. Phamacol., 86, 643-649, 2008.
`
` 5
`
`Page 5
`
`

`

`
`T.P. Johnston, X. Zhou, Oxidation of low-density-lipoprotein cholesterol following administration of
`poloxamer 407 to mice results from an indirect effect, J. Cardiovasc. Pharmacol. 49: 246-252, 2007.
`
`M. Chittchang, A.K. Mitra, and T.P. Johnston, Interplay of secondary structure and charge on the
`diffusion of a polypeptide through negatively-charged aqueous pores, Pharm. Res. 24: 502-511, 2007.
`
`C. Leon, K.M. Wasan, K. Sachs-Barrable, and T.P. Johnston, Acute P-407 administration to mice
`causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density
`lipoprotein receptor expression, Pharm. Res., 23, 1597-1607, 2006.
`
`T.P. Johnston, I.J. Goldberg, Inhibition of pancreatic lipase by poloxamer 407 may provide an
`adjunct treatment strategy for weight loss, J. Pharm. Pharmacol., 58, 1099-1105, 2006.
`
`T.P. Johnston, M.C. Jaye, C.L. Webb, J.A. Krawiec, S.P. Alom-Ruiz, K. Sachs-Barrable, and K.M.
`Wasan, Poloxamer 407 (P-407)-mediated reduction in the gene expression of ABCA1 may contribute
`to increased cholesterol in peripheral tissues of P-407-treated rats, Eur. J. Pharmacol., 536, 232-240,
`2006.
`
`N.T. Salamat-Miller, M. Chittchang, and T.P. Johnston, The use of mucoadhesive polymers in buccal
`drug delivery, Adv. Drug. Deliv. Rev., 57, 1666-1691, 2005.
`
`P. Pillutla, Y.C. Hwang, A. Augustus, M. Yokoyama, T.P. Johnston, M. Kaneko, R. Ramasamy, and
`I.J. Goldberg, Perfusion of hearts with triglyceride-rich particles reproduces the metabolic
`abnormalities in lipotoxic cardiomyopathy, Am. J. Physiol. Endocrinol. Metab., 288, E1229-E1235,
`2005.
`
`N.T. Salamat-Miller and T.P. Johnston, Current strategies used to enhance the paracellular transport
`of therapeutic polypeptides across the intestinal epithelium, Int. J. Pharm., 294, 201-216, 2005.
`
`N.T. Salamat-Miller, M. Chittchang, A.K. Mitra, and T.P. Johnston, A randomly-coiled, high-
`molecular-weight polypeptide exhibits increased paracellular diffusion in vitro and in situ relative to the
`highly-ordered a-helix conformer, Pharm. Res., 22(2), 245-254, 2005.
`
`C. Lindsey, M. Graham, A. Freshley, and T.P. Johnston, A clinical comparison of calculated versus
`direct measurement of low-density-lipoprotein cholesterol levels, Pharmacotherapy, 24, 167-172,
`2004.
`
`T.P. Johnston, The P-407-induced murine model of dose-controlled hyperlipidemia and
`atherosclerosis: A review of findings to date, J. Cardiovasc. Pharmacol, 43, 595-606, 2004.
`
`H.H. Alur, B. Jain, S. Dey, T.P. Johnston, B. Jasti, and A.K. Mitra, Physicochemical Factors Affecting
`Biological Activity, In: Theory and Practice of Contemporary Pharmaceutics, T.K. Ghosh and B.R.
`Jasti (Eds.) CRC Press, Boca Raton, FL (2004) pp. 83-136.
`
`K.N. Dileepan, T.P. Johnston, Y. Li, O. Tawfik, and D.J. Stechschulte, Deranged aortic intima media
`thickness, plasma triglycerides, and granulopoiesis in SI/SId mice, Med. of Inflamm., 13, 335-341,
`2004.
`
`K.M. Wasan, R. Subramanian, M. Kwong, I.J. Goldberg, T. Wright, and T.P. Johnston, Poloxamer
`407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats, J. Pharm.
`Pharmaceut. Sci., 6, 189-197, 2003.
`
`
`31.
`
`
`32.
`
`
`33.
`
`
`34.
`
`
`35.
`
`
`36.
`
`
`37.
`
`
`38.
`
`
`39.
`
`
`40.
`
`
`41.
`
`
`42.
`
`
`43.
`
`
`44.
`
`
`
`
` 6
`
`Page 6
`
`

`

`
`T.P. Johnston, K. Kuchimanchi, H.H. Alur, M. Chittchang, and A.K. Mitra, Inducing a change in the
`pharmacokinetics and biodistribution of poly-L-lysine in rats by complexation with heparin, J. Pharm.
`Pharmacol., 55, 1083-1090, 2003.
`
`T.P. Johnston, A.S. Jamal, D.N. Stechschulte, and K.N. Dileepan, Poloxamer 407-induced
`atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on
`endothelial cells and macrophages, Mediators of Inflamm., 12, 147-155, 2003.
`
`T.P. Johnston, N.T. Salamat, H.H. Alur, and A.K. Mitra, An attempt to modulate the microporous
`diffusion of a model polypeptide by altering its secondary structure, Drug Delivery, 10, 65-72, 2003.
`
`T.P. Johnston, C. Dias, H.H. Alur, and A.K. Mitra, Mucoadhesive Polymers in Ophthalmic Drug
`Delivery, In: Ophthalmic Drug Delivery Systems, A.K. Mitra (Ed.) Marcel Dekker, New York (2003)
`pp. 409-436.
`
`M. Martinez, L.A. Augsburger, T.P. Johnston, and W.W. Jones, Applying the biopharmaceutics
`classification system to veterinary pharmaceutical products, Part 1: Biopharmaceutics and
`formulation considerations, Adv. Drug Delivery Rev., 54, 805-824, 2002.
`
`H.H. Alur, A.K. Mitra, and T.P. Johnston, Polysaccharide-Based Mucoadhesive Buccal Tablets, In:
`Modified Release Drug Delivery Systems, M.D. Rathbone, J. Hadgraft, and M.S. Roberts (Eds.)
`Marcel Dekker, New York, NY (2002) pp. 401-418.
`
`N. Salamat-Miller, M. Chittchang, A.K. Mitra, and T.P. Johnston, Shape imposed by secondary
`structure of a polypeptide affects its free diffusion through liquid-filled pores, Int. J. Pharm., 244, 1-8,
`2002.
`
`M. Chittchang, N.T. Salamat, H.H. Alur, A.K. Mitra, and T.P. Johnston, Poly-L-lysine as a model drug
`macromolecule with which to investigate secondary conformation and membrane transport, Part 2:
`Diffusion studies, J. Pharm. Pharmacol., 54, 1497-1505, 2002.
`
`H.H. Alur, T.P. Johnston, and A.K. Mitra, Peptides and Proteins: Buccal Absorption, In: Encyclopedia
`of Pharmaceutical Technology, 2nd Edition, J. Swarbrick and J.C. Boylan, (Eds.) Marcel Dekker, New
`York, (2002) pp. 2081-2095.
`
`T.P. Johnston, J.W. Coker, O. Tawfik, and B.J. Paigen, Sex does not seem to influence the
`formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis,
`J. Cardiovasc. Pharmacol., 39, 404-411, 2002.
`
`M. Chittchang, N.T. Salamat, H.H. Alur, T.P. Johnston, and A.K. Mitra, Poly-L-lysine as a model drug
`macromolecule with which to investigate secondary conformation and membrane transport, Part 1:
`Physicochemical and stability studies, J. Pharm. Pharmacol., 54, 315-323, 2002.
`
`K.R. Kuchimanchi, M.D. Gandhi, R.R. Sheta, T.P. Johnston, K.C. Santhosh, M. Cushman, and A.K.
`Mitra, Intestinal absorption and biodistribution of cosalane and its amino acid conjugates – novel anti-
`HIV agents, Int. J. Pharm., 231, 197-211, 2002.
`
`R. Desai, S. Neau, S.I. Pather, and T.P. Johnston, Fine-particle ethylcellulose as a tablet binder in
`direct compression, immediate-release tablets, Drug Dev. Ind. Pharm., 27, 633-641, 2001.
`
`K.R. Kuchimanchi, M.S. Ahmed, T.P. Johnston, and A.K. Mitra, Binding of cosalane-a novel, highly-
`lipophilic anti-HIV agent-to albumin and glycoprotein, J. Pharm. Sci., 90, 657-664, 2001.
`
`
`45.
`
`
`46.
`
`
`47.
`
`
`48.
`
`
`49.
`
`
`50.
`
`
`51.
`
`
`52.
`
`
`53.
`
`
`54.
`
`
`55.
`
`
`56.
`
`
`57.
`
`
`58.
`
`
`
` 7
`
`Page 7
`
`

`

`
`59.
`
`
`60.
`
`
`61.
`
`
`62.
`
`
`63.
`
`
`64.
`
`
`65.
`
`
`66.
`
`
`67.
`
`
`68.
`
`
`69.
`
`
`70.
`
`
`71.
`
`
`72.
`
`
`73.
`
`
`R.J.J. Ramirez, J. Novak, T.P. Johnston, R.E. Gandley, M.K. McLaughlin, and C.A. Hubel,
`Endothelial function and myogenic reactivity in small mesenteric arteries of hyperlipidemic pregnant
`rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 281, R1330-R1337, 2001.
`
`T.P. Johnston, L. Nguyen, W.A. Chu, and S. Shefer, Potency of select statin drugs in a new mouse
`model of hyperlipidemia and atherosclerosis, Int. J. Pharm., 229, 75-86, 2001.
`
`H.H. Alur, A.K. Mitra, and T.P. Johnston, Inhibition of a model protease – pyroglutamate
`aminopeptidase – by a natural oligosaccharide gum from Hakea Gibbosa, Int. J. Pharm., 212, 171-
`176, 2001.
`
`H.H. Alur, T.P. Johnston, and A.K. Mitra, Peptides and Proteins: Buccal Absorption, In: Encyclopedia
`of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan (Eds), Vol. 20, Suppl. 3, Marcel Dekker,
`New York, 2001, pp. 193-218.
`
`K. Kuchimanchi, C. Udata, T.P. Johnston, and A.K. Mitra, Pharmacokinetics, biliary excretion, and
`tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague Dawley rats,
`Drug Metab. & Disp., 28(4), 403-408, 2000.
`
`T.P. Johnston, J.C. Baker, D. Hall, S. Jamal, E.E. Emeson, and W.K. Palmer, Regression of
`poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin, Atherosclerosis,
`149, 303-313, 2000.
`
`T.P. Johnston, J.C. Baker, D. Hall, S. Jamal, E.E. Emeson, and W.K. Palmer, Potential
`downregulation of HMG-CoA reductase following chronic administration of P-407 in C57BL/6 mice, J.
`Cardiovasc. Pharmacol., 34, 831-842, 1999.
`
`H.H. Alur, J.D. Beal, S.I. Pather, A.K. Mitra, and T.P. Johnston, Evaluation of a novel, natural
`oligosaccharide gum as a sustained-release and mucoadhesive component of calcitonin buccal
`tablets, J. Pharm. Sci., 88, 1313-1319, 1999.
`
`H.H. Alur, S.I. Pather, A.K. Mitra, and T.P. Johnston, Transmucosal delivery of chlorpheniramine
`maleate from a buccal tablet containing a natural, mucoadhesive gum, Int. J. Pharm., 188, 1-10,
`1999.
`
`H.H. Alur, I.S. Pather, A.K. Mitra, and T.P. Johnston, Evaluation of the gum Hakea Gibbosa as a
`sustained-release and mucoadhesive component in buccal tablets, Pharm. Develop. & Technol., 4,
`347-358, 1999.
`
`T.P. Johnston, A. Rahman, H.H. Alur, D. Shah, and A.K. Mitra, Permeation of unfolded basic
`fibroblast growth factor (bFGF) across rabbit buccal mucosa: Does unfolding of bFGF enhance
`transport? Pharm. Res., 15, 246-253, 1998.
`
`D. Shah, T.P. Johnston, S. Heitz, and A.K. Mitra, The effects of various excipients on the unfolding of
`basic fibroblast growth factor, J. Pharm. Sci. and Technol., 52, 209-214, 1998.
`
`D. Shah, T.P. Johnston, and A.K. Mitra, Thermodynamic parameters associated with guanidine HCl-
`and temperature-induced unfolding of basic fibroblast growth factor, Int. J. Pharm., 169, 1-14, 1998.
`
`C. Li, P.P. Bhatt, and T.P. Johnston, Evaluation of a mucoadhesive buccal patch for delivery of
`peptides: In vitro screening of bioadhesion, Drug Develop. & Indust. Pharm., 24, 919-926, 1998.
`
`T.P. Johnston, E.E. Emeson, and W.K. Palmer, Poloxamer 407-induced atherogenesis in the
`C57BL/6 mouse, Atherosclerosis, 136, 115-123, 1998.
` 8
`
`Page 8
`
`

`

`
`74.
`
`
`75.
`
`
`76.
`
`
`77.
`
`
`78.
`
`
`79.
`
`
`80.
`
`
`81.
`
`
`82.
`
`
`83.
`
`
`84.
`
`
`85.
`
`
`86.
`
`
`87.
`
`88.
`
`
`89.
`
`
`90.
`
`
`C. Li, P.P. Bhatt, and T.P. Johnston, Transmucosal delivery of oxytocin to rabbits using a
`mucoadhesive buccal patch, Pharm. Develop. & Technol., 2, 265-274, 1997.
`
`W.K. Palmer, E.E. Emeson, and T.P. Johnston, The poloxamer 407-induced hyperlipidemic
`atherogenic animal model, Med. Sci. Sports Exer., 29, 1416-1421, 1997.
`
`T.P. Johnston and W.K. Palmer, Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-
`methylglutaryl CoA reductase in rats, J. Cardiovasc. Pharmacol., 29, 580-585, 1997.
`
`T.P. Johnston and W.K. Palmer, The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA
`reductase obtained from poloxamer 407-induced hyperlipidemic rats, Pharmacotherapy, 17, 342-347,
`1997.
`
`C. Li, R.L. Koch, P.P. Bhatt, and T.P. Johnston, Absorption of thyrotropin releasing hormone in rats
`using a mucoadhesive buccal patch, Drug Develop. & Indust. Pharm., 23, 239-246, 1997.
`
`T.P. Johnston and P.P. Bhatt, Buccal Drug Delivery, Technomic Co., Lancaster, PA, pp. 1-315, ISBN
`1-56676-509-9, 1996.
`
`T.P. Johnston, Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to
`polyvinyl chloride, polypropylene, and glass: Effect of solvent additives, J. Pharm. Sci. & Technol., 50,
`238-245, 1996.
`
`C. Li, P.P. Bhatt, and T.P. Johnston, In vitro release and permeation of oxytocin from a
`mucoadhesive buccal patch, Pharm. Develop. & Technol., 1, 357-364, 1996.
`
`V.L. Nash, T.P. Johnston, and W.K. Palmer, Effects of nicotinic acid on poloxamer-induced
`hyperlipidemia, Pharmacotherapy, 16, 10-15, 1996.
`
`C. Li, W.K. Palmer, and T.P. Johnston, Disposition of poloxamer 407 following intraperitoneal
`injection to rats, J. Pharm. and Biomed. Anal., 14, 659-665, 1996.
`
`D. Hom, K. Medhi, G. Assefa, S. Juhn, and T.P. Johnston, Vascular effects of sustained fibroblast
`growth factors, Ann. Otology, Rhinology, Laryngology, 105, 109-116, 1996.
`
`J.A. Porter, B.L. Carter, T.P. Johnston, and W.K. Palmer, Effects of pravastatin on plasma lipid
`concentrations in hyperlipidemic rats, Pharmacotherapy, 15, 92-98, 1995.
`
`Wang, P. and Johnston, T.P., Sustained-release interleukin-2 following intramuscular injection in
`rats, Int. J. Pharm., 113, 73-81, 1995.
`
`Wang, P., Udeani, G.O., and T.P. Johnston, Inhibition of granulocyte colony stimulating factor (G-
`CSF) adsorption to polyvinyl chloride using a nonionic surfactant, Int. J. Pharm., 114, 177-184, 1995.
`
`Udeani, G.O., Bass, J., and Johnston, T.P., The compatibility of morphine sulfate solution with
`enteral feeding products, Annals Pharmacotherapy, 4, 432-438, 1994.
`
`Wang, P. and Johnston, T.P., Enhanced stability of two model proteins in an agitated solution
`environment using poloxamer 407, J. Parenter. Sci. and Technol. 47, 183-189, 1993.
`
`Johnston, T.P., Beris, H., and Kennedy, J.L., Effects on splenic, hepatic, hematological, and growth
`parameters following high-dose poloxamer 407 administration to rats, Int. J. Pharm., 100, 279-284,
`1993.
`
` 9
`
`Page 9
`
`

`

`
`Johnston, T.P. and Palmer, W.K., Mechanism of poloxamer 407-induced hypertriglyceridemia in
`the rat, Biochem. Pharmacol., 46, 1037-1042, 1993.
`
`Johnston, T.P., Webb, C., Schoen, F.J., and Levy, R.J., Site-specific delivery of ethanehydroxy
`diphosphonate from refillable polyurethane reservoirs to inhibit calcification of bovine pericardium
`used in bioprosthetic heart valves, J. Controlled Release, 25, 227-240, 1993.
`
`Wang, P. and T.P. Johnston, Thermal-induced denaturation of two model proteins: Effect of
`poloxamer 407 on solution stability, Int. J. Pharm., 96, 41-49, 1993.
`
`Wout, Z.G.M., Pec, E.A., Maggiore, J.A., Williams, R.H., and Johnston, T.P., Poloxamer 407-
`mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection in the rat,
`J. Parenter. Sci. and Technol., 46, 192-200, 1992.
`
`Johnston, T.P., Webb, C.L., Schoen, F.J., and Levy, R.J., Assessment of the in vitro transport
`parameters for ethanehydroxy diphosphonate through a polyurethane membrane: A potential refillable
`reservoir drug delivery device, ASAIO Journal, 38, 611-616, 1992.
`
`Pec, E.A., Wout, Z., and Johnston, T.P., Biological activity of urease formulated in poloxamer 407
`following intraperitoneal injection in the rat, J. Pharm. Sci., 81, 626-630, 1992.
`
`Johnston, T.P., Punjabi, M.A., and Froelich, C.J., Sustained delivery of interleukin-2 from a
`poloxamer 407 gel matrix following intraperitoneal injection in mice, Pharm. Res., 9, 421-430, 1992.
`
`Levy, R.J., Bolling, S.F., Siden, R., Kadish, A., Pathak, Y., Dorostkar, P., Sintov, A., Golomb, G., and
`T.P. Johnston, Polymeric Controlled Release of Cardiovascular Drugs, In: Cosmetic and
`Pharmaceutical Applications of Polymers, Ed., C.G. Gebelein, Plenum Publishing Corporation, New
`York, NY (1991) pp. 231-238
`
`P. Wang and T.P. Johnston, The kinetics of the sol-to-gel transition for poloxamer polyols, J. Appl.
`Polymer Sci., 43, 283-292, 1991.
`
`Y.V. Pathak, J.A. Boyd, T.P. Johnston, J.T. Levy, G. Golomb, F.J. Schoen, and R.J. Levy, Scanning
`electron microscopy studies of the prevention of bioprosthetic heart valve calcification with controlled
`release polymeric matrices, Cells & Materials, Vol. 1, No. 1, 65-72, 1991.
`
`K.A. Fults and T.P. Johnston, Sustained release of urease from a poloxamer gel matrix, J. Parent.
`Sci. and Technol., 44, 58-65, 1990.
`
`T.P. Johnston, J.A. Boyd, B.L. Ciesliga, F.J. Schoen, and R.J. Levy, Controlled release of
`1-hydroxyethylidene diphosphonate from polyurethane reservoirs to inhibit calcification of bovine
`pericardium used in bioprosthetic heart valves, Int. J. Pharm., 59, 95-104, 1990.
`
`T.P. Johnston and S.C. Miller, Inulin disposition following intramuscular administration of an
`inulin/poloxamer gel matrix, J. Parent. Sci. and Technol., 43, 279-286, 1989.
`
`T.P. Johnston and R.J. Levy, Characterization of a polyurethane membrane used for the sustained
`delivery of 1-hydroxyethylidene diphosphonate, Proceed. Intern. Symp. Control. Rel. Bioact. Mater.,
`16, 322-323, 1989.
`
`
`91.
`
`
`92.
`
`
`93.
`
`
`94.
`
`
`95.
`
`
`96.
`
`
`97.
`
`
`98.
`
`
`99.
`
`
`100.
`
`
`101.
`
`
`102.
`
`
`104.
`
`
`105.
`
`
`
`
`103. R.J. Levy, T.P. Johnston, A. Sintov, and G. Golomb, Controlled release implants for cardiovascular
`disease, J. Controlled Release, 11, 245-254, 1990.
`
` 10
`
`Page 10
`
`

`

`
`T.P. Johnston, E.L. Bove, S.F. Bolling, J.A. Boyd, B.L. Ciesliga, F.J. Schoen, G.L. Amidon, and
`R.J. Levy, Controlled release of 1-hydroxyethylidene diphosphonate: In vitro assessment and effects
`on bioprosthetic calcification in sheep tricuspid valve replacements, Int. J. Pharm., 52, 139-148, 1989.
`
`T.P. Johnston, E.L. Bove, S.F. Bolling, F.J. Schoen, J.A. Boyd, G. Golomb, and R.J. Levy, Local
`controlled release of 1-hydroxyethylidene diphosphonate using silicone-rubber matrices: Effects of
`sterilization on in vitro release and in vivo efficacy, ASAIO Trans., 34, 835-838, 1988.
`
`T.P. Johnston, F.J. Schoen, and R.J. Levy, Prevention of calcification of bioprosthetic heart valve
`leaflets by calcium diphosphonate pretreatment, J. Pharm. Sci., 77, 740-744, 1988.
`
`T.P. Johnston and S.C. Miller, Toxicological evaluation of poloxamers for intramuscular use, J.
`Parent. Sci. Technol., 39, 83-88, 1985.
`
`Abstracts and Presentations:
`
`Intentionally left blank
`
`T.P. Johnston, T.A. Korolenko, Y.A. Kisarova, T.V. Alexeenko, N.I. Dubrovina, E.E. Filjushina, M.S.
`Cherkanova, N.A. Zhukova, E. Machova. Effect of poloxamer 407 administration on serum lipids,
`anxiety level and protease activity in the heart and liver of mice. 28th Annual Meeting of the American
`Association of Pharmaceutical Scientists, San Diego, CA, Nov. 2014.
`
`V.M. Loginova, T.A. Korolenko, T.P. Johnston, F.V. Tuzikov, Ts.P. Korolenko, I.N. Maiborodin, V.K.
`Spiridonov. Lipoprotein fractions and subfractions in a murine model of early atherosclerosis,
`International Academy of Cardiology, 19th World Congress on Heart Disease: Annual Scientific
`Sessions, Boston, USA, July, 2014.
`
`T.A. Korolenko, T.P. Johnston, F.V. Tuzikov, E.E. Pisareva, E.E. Filjushina, V.M. Loginova.
`Poloxamer 407-induced lipidosis in mice and involvement of lysosomes. 19th European Study Group
`on Lysosomal Diseases (ESGLD), Graz, Austria. Sept. 2013.
`
`T.P. Johnston, T.A. Korolenko, E.E. Filjushina, N.A. Tuzikova, F.V. Tuzikov, N.A. Zhukova..
`Atherosclerosis resulting from sustained dyslipidemia: The role of cardiac proteases and serum
`chitotriosidase as biomarkers of early heart disease. 27th Annual Meeting of the American
`Association of Pharmaceutical Scientists, San Antonio, TX, Nov. 2013.
`
`V.M. Loginova, T.A. Korolenko, T.P. Johnston, F.V. Tuzikov, S.Y. Zhanaova, N.V. Goncharova.
`Lipoprotein fractions and subfractions and heart proteases in acute lipemia and murine model of
`atherosclerosis. International Academy of Cardiology, 18th World Congress on Heart Disease: Annual
`Scientific Sessions, Vancouver, British Columbia, Canada, July, 2013.
`
`T.P. Johnston, D.J. Waxman. Peroxisome proliferator-activated receptor (PPAR) agonists and their
`role in dyslipidemia and atherosclerosis, Kansas City Area Life Sciences Research Day Summit,
`Kansas City, MO, April, 2012.
`
`Thomas P. Johnston, Tomoyuki Yasuda, Masakazu Shinohara, Michihiko Inoue, Tatsuro Ishida.
`The effect of poloxamer 407 on the functional properties of HDL In mice. 25th Annual Meeting of the
`American Association of Pharmaceutical Scientists, Washington, DC, Oct. 2011.
`
`
`106